Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Satellos Bioscience ( (TSE:MSCL) ) has provided an announcement.
On February 18, 2026, Satellos Bioscience Inc. announced it will host a virtual key opinion leader event on February 24, 2026, featuring neuromuscular expert Dr. Kevin M. Flanigan to discuss the unmet need and current treatment landscape in Duchenne muscular dystrophy. The event will highlight clinical progress for SAT-3247, including Phase 1a/b data in healthy volunteers and adults with DMD, the TRAILHEAD open-label adult study, and the BASECAMP randomized Phase 2 pediatric trial, underscoring Satellos’ efforts to position SAT-3247 as a potentially disease-modifying, dystrophin-independent therapy in a competitive DMD market.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on TSE:MSCL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.
To see Spark’s full report on TSE:MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotechnology company developing orally administered small molecule medicines to restore natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, targets the AAK1 protein to address disrupted muscle stem-cell signaling in Duchenne muscular dystrophy (DMD) and is being evaluated in ongoing Phase 2 clinical trials in adult and pediatric patients.
Average Trading Volume: 32,482
Technical Sentiment Signal: Buy
Current Market Cap: C$243.3M
See more data about MSCL stock on TipRanks’ Stock Analysis page.